

## LIBERIA Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Liberia					
<b>2. Grant number:</b> 1820-LBR-12d-X /13-LBR-08c-Y / 18-LBR-25a-Y					
<b>3. Date of Decision Letter:</b> 15 May 2018					
<b>4. Date of the Partnership Framework Agreement:</b> 19 August 2013					
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine					
<b>6. Vaccine type:</b> Pneumococcal					
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 1 dose per vial, LIQUID, Pneumococcal (PCV13), 4 doses per vial, LIQUID					
<b>8. Programme duration<sup>1</sup>:</b> 2013 - 2020					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2014-2017	2018	2019	2020	Total <sup>2</sup>
Programme Budget (US\$)	6,898,210 <sup>3</sup>	1,777,000	1,842,500	1,990,500	12,508,210
<b>10. Vaccine introduction grant (in US\$) / Product switch grant:</b> US\$ 155,000 already disbursed to Liberia on 18 November 2013. <b>Country is eligible for Product Switch Grant of US\$ 46,007 to support the PCV Switch.</b>					
<b>11. Gavi Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>					
<b>Number of vaccines to be purchased with Gavi funds each year</b>	<b>2014-2017</b>	<b>2018</b>			
Pneumococcal Routine Programme (doses)		529,000			
Annual Amounts (US\$)		1,777,000			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**13. Self-procurement:** Not applicable

**14. Co-financing obligations:** Reference code: 1820-LBR-12d-X-C  
According to the co-financing policy, the Country falls within the group Initial self-financing.  
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<b>Number of vaccines to be purchased with Gavi funds each year</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
Number of vaccine doses	37,000	36,800	38,400
Value of vaccine doses (US\$)	112,521		
Total co-financing payments (US\$) (including freight)	113,500	113,000	117,500

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:**

<b>Reports and other information</b>	<b>Due dates</b>
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not applicable

18. **Other conditions:** Not applicable

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes  
15 May 2018